From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.30
First Reported 2007
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 8
Total Number 8
Disease Relevance 2.99
Pain Relevance 0.50

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleoplasm (RARA) signal transduction (RARA) nucleus (RARA)
enzyme binding (RARA) transcription factor binding (RARA) cytoplasm (RARA)
RARA (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 28 100.00 Very High Very High Very High
Inflammation 57 87.68 High High
dexamethasone 48 79.32 Quite High
corticosteroid 8 60.64 Quite High
Spinal cord 24 60.32 Quite High
Neuropathic pain 1 46.92 Quite Low
depression 1 46.20 Quite Low
headache 2 20.36 Low Low
agonist 40 5.00 Very Low Very Low Very Low
allodynia 6 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Breast Cancer 67 96.04 Very High Very High Very High
Neuroblastoma 46 94.68 High High
Apoptosis 62 93.80 High High
Rheumatoid Arthritis 89 91.52 High High
Cancer 176 88.96 High High
INFLAMMATION 62 87.68 High High
Disease 16 87.52 High High
Emphysema 1 81.04 Quite High
Bronchopulmonary Dysplasia 9 72.88 Quite High
Carcinoma 15 71.52 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
ATRA increases the activity of the human COX-2 promoter and its effect is inhibited by RAR-pan-antagonist LE540 or MEK-1 inhibitor PD98059
Negative_regulation (inhibitor) of RAR-pan-antagonist LE540 associated with antagonist
1) Confidence 0.30 Published 2007 Journal J Neuroinflammation Section Body Doc Link PMC1769480 Disease Relevance 0.30 Pain Relevance 0.11
In this context, the abolition by RAR pan-antagonist LE540 of ATRA-induced COX-2 promoter activation (Figure 2d) is more likely due to the inhibition of a RAR-dependent effect on an unidentified target.
Negative_regulation (inhibition) of RAR-dependent associated with antagonist
2) Confidence 0.30 Published 2007 Journal J Neuroinflammation Section Body Doc Link PMC1769480 Disease Relevance 0.13 Pain Relevance 0.08
SNIP (p = 0.0002), MLLT6 (p = 0.0072), CISD3 (p = 0.0111), PCGF2 (p = 0.0067), PSMB3 (p = 0.0029), PIP4K2B (p = 0.0126), FBXL20 (p = 0.0324), STARD3 (p = 0.0318), GRB7 (p = 0.0244) and RARA (p = 0.0201) were downregulated in ERBB2-amplified IBCs compared to ERBB2-amplified NIBCs.
Negative_regulation (downregulated) of RARA
3) Confidence 0.27 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2958950 Disease Relevance 0.63 Pain Relevance 0.22
The retinoid/trastuzumab combination resulted in enhanced inhibition of MAPK signaling and downregulation of RAR?
Negative_regulation (downregulation) of RAR
4) Confidence 0.24 Published 2010 Journal Breast Cancer Res Section Body Doc Link PMC2949655 Disease Relevance 0.70 Pain Relevance 0
LBD impairs the transcriptional activity of RXR/RAR [21, 22] and RXR/vitamin D3 receptor (VDR) [23].
Negative_regulation (impairs) of RAR
5) Confidence 0.23 Published 2008 Journal PPAR Research Section Body Doc Link PMC2408709 Disease Relevance 0.74 Pain Relevance 0
The latter include the PPARs, vitamin D (VDR), and retinoic acid (RAR)
Negative_regulation (include) of RAR
6) Confidence 0.08 Published 2008 Journal PPAR Research Section Body Doc Link PMC2423003 Disease Relevance 0.06 Pain Relevance 0
Indeed, deletion or inhibition of RAR results in reduced elastin and alveolar simplification [40,41].
Negative_regulation (inhibition) of RAR
7) Confidence 0.08 Published 2009 Journal Respir Res Section Body Doc Link PMC2739515 Disease Relevance 0.42 Pain Relevance 0.10
These mutations include RXR A416D or R421L, which specifically disrupt the formation of the RXR/TR heterodimer, and RXR A416K, which disrupts RXR/RAR and RXR/TR [58].
Negative_regulation (disrupts) of RAR
8) Confidence 0.06 Published 2009 Journal PPAR Research Section Body Doc Link PMC2801013 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools